Lonza raises Sfr2.25bn in successful Capsugel rights issue

By Jon Hay
11 May 2017

Lonza, the Swiss pharmaceuticals group, has completed its Sfr2.25bn rights issue, to part-finance its takeover of Capsugel, the US maker of medicine capsules, from KKR.

UBS and Bank of America Merrill Lynch were global coordinators, with Credit Suisse, Citigroup, Goldman Sachs and JP Morgan bookrunners.

Commerzbank, HSBC, Julius Baer and Mizuho were co-managers and Banca Imi, BNP Paribas, Helaba, LBBW, MUFG and Zürcher Kantonalbank underwriters.

By noon Swiss time on Wednesday, 99.25% of ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.